Opinion

Video

Treatment Options for HS

Gina Mangin, MPAS, PA-C, reviews current treatment options for patients with HS, highlighting adalimumab as well as non-FDA approved therapies.

Gina Mangin, MPAS, PA-C: The treatment options that we have for HS [hidradenitis suppurativa] are extensive. We know that HS is this chronic, recurrent, inflammatory disease that’s involving the hair follicle. The only FDA-approved medication that we have for HS is adalimumab, which is an injection that patients administer themselves, but there are other things that we use that aren’t necessarily FDA approved. There are tons of medical literature out there supporting the use of these medications, which include oral antibiotics, intralesional steroid injections, and oral immunosuppressive medications. Other things we will use are medications that may affect the hormone imbalances, meaning oral birth control pills, or oral spironolactone. We will also use topical antibiotics, topical resorcinol. So, the list is large in terms of the treatment options that we have out there.

The next question is, how do we treat these patients and how do we decide which treatment modalities to use? The first question is, is their disease mild or is it more moderate and severe? If it’s mild, then we can probably just use some topical antibiotics. If they have a flare, then we can use intralesional cortisone injection. But if they’re having a flare, the key is that we must calm that inflammation down. Often when we’re going to start with oral anti-inflammatory antibiotics, if we see that these flares are continually progressing and we’re seeing that they have scarring along with the tunnels and the tracks forming, then many times we’re going to combine medications such as adalimumab and oral antibiotics but also…surgical treatments as well. I failed to mention earlier that those are treatments too—surgical treatments, removing those cysts or deroofing those cysts. When your patients’ symptoms are severe, they’re going to need both medical and surgical intervention.

Transcript edited for clarity

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Atypical Clinical Presentations of Blistering Disease, with Donna Culton, MD, PhD
How to Address Blistering Diseases, with Donna Culton, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.